CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA) için istatistikler
Toplam ziyaret
| views | |
|---|---|
| CARMEN-GC01: Phase II, open-label, single-arm study of tusamitamab ravtansine in combination with ramucirumab in pretreated patients with gastric or gastroesophageal junction adenocarcinoma (GA/GEJA) | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Haziran 2025 | 0 |
| Temmuz 2025 | 0 |
| Ağustos 2025 | 0 |
| Eylül 2025 | 0 |
| Ekim 2025 | 0 |
| Kasım 2025 | 0 |
| Aralık 2025 | 0 |
